Cassava Sciences Discontinues Developing Simufilam For Alzheimer's After Another Phase 3 Trial Flop
1. Cassava's Phase 3 REFOCUS-ALZ study results were disappointing. 2. Simufilam did not meet cognitive and functional endpoints. 3. The drug development program for Alzheimer's will be terminated. 4. Cassava plans to phase out the Alzheimer's program by Q2 2025. 5. Stock declined 22.1%, reflecting market disappointment.